Is JNJ stock a buy right now?
As of early May 2025, Johnson & Johnson (JNJ) shares are trading near $154.46, with an average daily trading volume of about 9.7 million shares—a healthy level of investor engagement on the NYSE. Over the past quarter, JNJ has shown financial resilience, outperforming expectations in its recent Q1 report and delivering revenue of $21.89 billion, with adjusted earnings per share well above consensus. One significant recent milestone is the FDA approval of IMAAVY™ for generalized myasthenia gravis, reinforcing the company's reputation for pharmaceutical innovation. Market sentiment is constructive despite short-term technical indicators showing some caution, as JNJ’s diversified approach and dividend history continue to inspire confidence among analysts and investors alike. Within the healthcare sector, JNJ stands out not only for its long record of dividend growth but also for its strategic investments in R&D and expansion across medical technology. Reflecting this positive outlook, the consensus price target of more than 30 national and international banks points to $200.80, highlighting sustained optimism for the stock’s medium-term performance. For Canadian investors seeking quality, stability, and potential for growth in their portfolios, JNJ’s profile remains compelling even amid sector shifts.
- Robust dividend growth for over 60 years, appealing to income-focused investors.
- Diversified revenue across pharmaceuticals and medical technology reduces business risk.
- Multiple product lines hold global leadership positions in their categories.
- Strong operational cash flow supports strategic investments and shareholder returns.
- Recent FDA approvals and pipeline innovation drive future growth potential.
- Ongoing patent expirations could temporarily impact pharmaceutical revenue streams.
- Short-term technical signals point to near-term volatility or sideways movement.
- What is JNJ?
- How much is JNJ stock?
- Our full analysis on JNJ </b>stock
- How to buy JNJ stock in Canada?
- Our 7 tips for buying JNJ stock
- The latest news about JNJ
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the JNJ stock performance for over three years. Each month, hundreds of thousands of users across Canada rely on our insights to understand market trends and spot the most promising investment opportunities. Our analyses are provided for informational purposes only and should not be interpreted as investment advice. In line with our ethical charter, we have never been, and will never be, compensated by JNJ.
What is JNJ?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | JNJ is headquartered in the U.S., making it subject to U.S. regulations and laws. |
| 💼 Market | NYSE (New York Stock Exchange) | Listed on the NYSE, offering strong liquidity and global investor access. |
| 🏛️ ISIN code | US4781601046 | The ISIN uniquely identifies JNJ for global trading and transparency. |
| 👤 CEO | Joaquin Duato | Joaquin Duato has led JNJ as CEO since January 2022, focusing on innovation. |
| 🏢 Market cap | $371.64 billion | JNJ’s large market cap reflects stability and market leadership in healthcare. |
| 📈 Revenue | $89.9–$90.7 billion (projected 2025) | Solid revenue growth, with management guiding higher sales despite patent headwinds. |
| 💹 EBITDA | ~$28.5 billion (2024 actual) | Strong EBITDA supports robust cash flow and ongoing shareholder returns. |
| 📊 P/E Ratio (Price/Earnings) | 17.18 | The P/E is slightly below its sector, signaling reasonable valuation and moderate growth. |
How much is JNJ stock?
The price of JNJ stock is declining today. As of now, Johnson & Johnson shares are trading at $154.46 USD, down 1.18% over the past 24 hours but up 0.79% this week. The company’s market capitalization stands at $371.64 billion, with a 3-month average daily volume of 9.69 million shares. JNJ trades at a price-to-earnings ratio of 17.18, offering a dividend yield of 3.37% and a beta of 0.48, which signals lower volatility than the general market.
For Canadian investors seeking stable, income-generating assets, JNJ combines resilience and a longstanding commitment to dividends while maintaining modest price fluctuations.
Compare the best brokers in Canada!Compare brokersOur full analysis on JNJ stock
Having reviewed Johnson & Johnson’s (JNJ) latest financial results alongside the stock’s performance over the past three years, it is clear that this healthcare leader continues to exhibit resilience and strategic agility. By leveraging a comprehensive blend of financial ratios, technical indicators, peer analysis, and proprietary modeling, we have systematically analyzed both the risks and upside potential inherent in JNJ’s current market positioning. So, why might JNJ stock once again become a strategic entry point into the US and global healthcare sector as 2025 unfolds?
Recent Performance and Market Context
In 2024 and into 2025, Johnson & Johnson has displayed notable stability despite macroeconomic fluctuations and sector-specific headwinds. As of May 2, 2025, JNJ shares trade at $154.46, reflecting a modest gain of +2.17% year-over-year and a slight dip (-3.54%) over the past six months. The stock demonstrates resilience, consistently outperforming sector peers during periods of volatility, supported by robust market capitalization of $371.64 billion.
- Q1 2025 financial outperformance: Revenue reached $21.89 billion (+2.4% year-over-year), exceeding analyst expectations and confirming operational growth at +4.2%.
- FDA approval (April 30, 2025): IMAAVY™ (nipocalimab-aahu), JNJ’s innovative FcRn blocker for generalized myasthenia gravis, marks a significant advance in its specialty pharmaceutical portfolio.
- Analyst confidence boost: The addition of JNJ to Goldman Sachs’ US Conviction List underscores continued institutional faith in the company’s near- and mid-term prospects.
The current macroeconomic context—marked by persistent healthcare demand, ongoing innovation, and North American resilience to global economic uncertainty—creates a constructive environment for integrated healthcare companies. JNJ’s diversified operations allow it to weather patent cliffs and regulatory changes more adeptly than many competitors, further solidifying its appeal in defensive, late-cycle portfolios.
Technical Analysis
While the short-term technical picture for JNJ is mixed, it is precisely this backdrop that often precedes compelling long-term entry points for patient investors:
Current Indicators
- RSI (14): 45.75 — A neutral reading, indicating neither overbought nor oversold conditions, suggesting the potential for renewed upward momentum from a balanced base.
- MACD (12,26,9): -0.79 — Slightly bearish, yet this historically has marked contrarian buy windows as mean reversion occurs following periods of temporary weakness.
- Moving Averages:
- The stock trades below its 20, 50, 100, and 200-day moving averages (all clustered around $155–$156), pointing to mild short-term selling pressure.
- These moving averages now serve as targets for a bullish reversal, a pattern frequently witnessed in blue-chip defensive names following technical retracements.
Key Support and Resistance
- Support levels: Robust support at $151.64 and $153.33, limiting downside and offering strategic entry points for risk-managed accumulation.
- Resistance: Short-term upside catalysts will test resistance at $158.00 and $159.69; a break above these thresholds may inaugurate a fresh bullish phase.
Momentum Structure
Though recent technicals lean bearish, the confluence of strong support and positive fundamental news flow increases the likelihood of a reversal. Historically, JNJ’s periods of technical consolidation have preceded significant rallies, particularly when corroborated by improving fundamentals.
Fundamental Analysis
- Revenue and profit growth: The company delivered $21.89 billion in Q1 2025 revenues (+2.4% YOY), beating consensus. Adjusted EPS of $2.77 not only surpassed expectations by 7.78% but also underscored operational leverage.
- Valuation remains attractive: Trading at a forward P/E of 17.18 and a dividend yield of 3.37%, the stock appears attractively valued both relative to its historical ranges and sector peers. The PEG ratio and price-to-sales metrics remain well within long-term norms, supported by consistent free cash flow generation.
- Business model strength: JNJ maintains a unique blend of pharmaceutical innovation and market dominance in MedTech. More than 75% of sales stem from #1 or #2 global market share products.
- Market leadership and brand: Over 60 consecutive years of dividend increases—qualifying JNJ as a “Dividend Aristocrat”—testifies to both franchise value and shareholder alignment.
- Strategic expansion: Management projects FY2025 revenues of $89.9–$90.7 billion and EPS of $10.25–$10.45, with over $55 billion earmarked for US investments over the next four years.
Moreover, despite challenges such as the STELARA patent expiry, JNJ’s robust pipeline—including new products like Tremfya, Carvykti, and freshly approved IMAAVY™—position the company to replenish growth engines and reinforce its leadership.
Volume and Liquidity
- Average daily trading volume: At 9.69 million shares, the stock offers ample liquidity for institutional and retail participants alike.
- Wide float and depth: Deep institutional ownership and a broad float underpin price discovery and stability, reducing volatility and enhancing confidence in the stock’s dynamic valuation.
- Market confidence: Sustained volume near technical support zones typically signals informed accumulation—a pattern observable in JNJ’s recent trading behavior.
Catalysts and Positive Outlook
Looking ahead, several positive catalysts are poised to reinforce JNJ’s value proposition:
- New product launches and regulatory approvals: Recent news such as the FDA’s greenlight for IMAAVY™ and ongoing success with immunological and oncology drugs (Tremfya, Carvykti) highlight JNJ’s capacity for innovation-driven growth.
- Strategic investments: The announced $55 billion capex plan in the US over four years speaks to long-term confidence in both organic and acquired growth pathways.
- ESG momentum: JNJ continues to advance in sustainable healthcare, integrating robust ESG practices that meet evolving regulatory and investor expectations.
- Resilient sector backdrop: With healthcare spending trends remaining positive across North America, and aging demographics fueling sustained demand, JNJ appears well-placed to benefit from both cyclical upswings and defensive flows.
- Acquisition potential: The company’s cash-rich balance sheet enables opportunistic M&A, further bolstering future growth.
These drivers, coupled with analyst consensus suggesting nearly 10% upside to target price, justify a constructive outlook even as headline risks are carefully monitored.
Investment Strategies
Given the technical, fundamental, and strategic context, JNJ offers robust arguments for consideration across multiple investment horizons:
Short-term positioning
- Technical low accumulation: With current pricing near multi-month support, disciplined entry at or just above $153 offers favorable risk/reward for traders targeting a bounce toward resistance levels ($158–$160).
- Event-driven upside: FDA approvals and quarterly earnings often serve as catalysts for momentum plays, historically delivering outsized moves in JNJ relative to its low-beta profile.
Medium-term approach
- Pipeline news flow: Anticipated trial results, additional product launches (especially in immunology and MedTech), and milestone achievements present episodic catalysts for stock re-rating.
- Sector rotation benefits: Healthcare’s traditional outperformance in uncertain macro environments supports a medium-term thesis of renewed institutional inflows, especially for dividend-focused investors.
Long-term core holding
- Dividend growth and compounding: JNJ’s over 60 years of dividend increases, disciplined capital allocation, and sustained FCF generation present a compelling long-term hold thesis for investors seeking defensive growth and stable income.
- Structural innovation: Ongoing R&D investment, coupled with aggressive US capital deployment, suggest a multi-year runway for earnings expansion and value accretion.
- Portfolio anchor: For Canadian investors with cross-border allocations, JNJ serves as a high-quality USD-denominated core holding with proven crisis resilience.
Is it the Right Time to Buy JNJ?
In summary, Johnson & Johnson’s blend of financial discipline, operating scale, and relentless innovation continues to set the company apart within global healthcare. Technical indicators, while currently mixed, are counterbalanced by strong support levels and a history of mean-reverting rallies following periods of consolidation. Fundamentally, JNJ’s attractive valuation, outstanding dividend record, dominant market share positions, and a forward-looking strategic vision provide a bedrock for optimistic forecasts.
With new product launches fueling growth, ambitious investment plans underway, and clear institutional confidence as evidenced by inclusion in major conviction lists, the stock seems poised for renewed upside. For investors seeking a blend of stability, income, and long-term growth in the healthcare sector, JNJ appears to represent an excellent opportunity at current levels—a potential entry point before the next phase of acceleration. As always, monitoring evolving sector dynamics and key pipeline milestones will be essential, but the evidence strongly supports renewed consideration of JNJ as a core holding in 2025 portfolios.
In this context, JNJ stands out as a high-quality name whose compelling value proposition today may well be recognized by tomorrow’s market—providing an attractive vantage point for investors attentive to both the present opportunity and the company’s robust, innovation-driven future.
How to buy JNJ stock in Canada?
Buying Johnson & Johnson (JNJ) stock online is simple and secure when using a regulated Canadian broker. You can invest directly in JNJ shares (“spot” buying), making you an actual shareholder, or trade a contract for difference (CFD), which lets you speculate on price movements with leverage. Both approaches are accessible through major online trading platforms, each with its own benefits and risks. Further down this page, you’ll find a comprehensive comparison table to help you choose the Canadian broker that best suits your needs.
Spot Buying
A spot purchase means buying Johnson & Johnson shares outright on the stock market—you become a direct shareholder and are eligible for dividends. With Canadian brokers, the typical fee structure is a flat commission per order, generally around $5 to $10 CAD, plus any currency conversion costs, since JNJ trades in USD.
Important example
Example: If the JNJ share price is $154.46 USD (about $210 CAD), with $1,000 CAD you could buy approximately 4 shares (accounting for currency conversion and a $5 commission).
✔️ Gain scenario: If the share price rises by 10%, your holdings would now be worth about $1,100 CAD. Result: +$100 gross gain—that’s a 10% return on your investment (excluding currency fluctuations).
Trading via CFDs
CFDs (Contracts for Difference) allow you to speculate on JNJ’s price changes without owning the actual shares. Available at many Canadian online brokers, CFDs offer access to leverage—meaning you can control a larger position using less capital. Fees are typically built into the spread (the difference between buy and sell prices), plus an overnight financing fee if you hold positions open for more than a day.
Important example
Example: With a $1,000 CAD stake and 5x leverage, you gain exposure to $5,000 CAD worth of JNJ shares.
✔️ Gain scenario: If the stock rises by 8%, your CFD position returns 8% × 5 = 40%, giving a +$400 gain on your initial $1,000 stake (excluding fees).
Final Advice
It’s important to compare broker fees, currency conversion rates, and trading conditions before investing. Your ideal approach—direct share ownership or leveraged CFD trading—depends on your investment objectives and risk tolerance. For a side-by-side overview of leading Canadian brokers and their costs, check out our comparison table further down this page. Remember, investing in JNJ can be both accessible and rewarding with the right broker and strategy tailored to your needs.
Our 7 tips for buying JNJ stock
| 📊 Step | 📝 Specific tip for JNJ |
|---|---|
| Analyze the market | Evaluate JNJ’s financial performance and current stock price trends, noting both its stable long-term growth and short-term technical caution highlighted by its position below key moving averages. |
| Choose the right trading platform | Pick a Canadian broker offering access to the NYSE with competitive foreign exchange rates and the ability to hold USD, optimizing your returns when buying JNJ shares. |
| Define your investment budget | Set an investment amount appropriate for your goals and risk tolerance; consider that JNJ’s solid dividend and low volatility make it suitable for moderate to large, long-term positions. |
| Choose a strategy (short or long term) | Opt for a long-term strategy to capitalize on JNJ’s strong dividend growth and historical stability, while being prepared for short-term fluctuations due to sector challenges. |
| Monitor news and financial results | Regularly review JNJ’s quarterly reports, FDA approvals, and Canadian and US healthcare policy developments, which can drive both short- and long-term price movements. |
| Use risk management tools | Utilize stop-loss orders and diversify your portfolio with other sectors to manage potential risks from patent expirations or regulatory changes affecting JNJ. |
| Sell at the right time | Consider taking profits if JNJ hits major resistance levels or if upcoming events—such as a significant change in dividend policy—alter its long-term outlook. |
The latest news about JNJ
Johnson & Johnson's Q1 2025 results exceeded analyst expectations, with Canadian investors benefitting from stable dividend income. Reported on April 15, 2025, JNJ delivered $21.89 billion in revenue, surpassing consensus estimates and showcasing 2.4% year-over-year growth. Adjusted EPS reached $2.77, reflecting an almost 8% surprise to the upside. This strong operational performance affirms the company's ability to generate reliable, inflation-resistant cash flows—an especially key consideration for Canadian investors seeking stable income stocks in a challenging macro environment. JNJ’s status as a Dividend Aristocrat, with over 60 years of uninterrupted dividend increases, also assures Canadian shareholders of continued income, and dividends paid by JNJ generally receive favorable tax treatment under Canada-US tax agreements when held in registered Canadian accounts.
The FDA’s approval of IMAAVY™ (nipocalimab-aahu) for generalized myasthenia gravis reinforces JNJ’s innovative edge and future growth, with significance in Canada’s healthcare market. Granted on April 30, 2025, this approval enhances JNJ’s leading pharmaceutical portfolio and demonstrates its ability to advance high-value treatments—vital for Canada, where neuromuscular diseases like gMG require innovative therapies and demand continues to rise. Canadian healthcare providers frequently adopt therapies approved by US and global regulatory agencies, increasing the likelihood of swift market entry and subsequent sales growth in Canada’s public and private healthcare systems.
Goldman Sachs’s recent addition of JNJ to its US Conviction List signals renewed institutional confidence, likely influencing Canadian sentiment given cross-listed status. This inclusion represents a strong vote of confidence from a leading global investment bank and tends to positively impact the broader North American investor base, including numerous Canadian institutional and retail holders. JNJ’s cross-listing on the Toronto Stock Exchange via DRIP programs and prevalent ETF inclusion makes such endorsements particularly relevant for Canadian investment portfolios, potentially improving liquidity and capital inflow from Canada into Johnson & Johnson shares.
JNJ’s diversified portfolio and innovation pipeline, including robust performance from Tremfya and Carvykti, continue to offset patent risks, sustaining its relevance for Canadian investors. Despite the expiration of STELARA’s patent, JNJ’s growth in products like Tremfya and Carvykti is underpinning revenue stability. This is particularly meaningful for Canadian risk-conscious investors who value fundamental business resilience—especially as JNJ maintains dominant positions in both the pharmaceutical and MedTech markets. The company’s ongoing strategic investments, exceeding $55 billion through the next four years, are set to further solidify its position as a healthcare leader with direct and indirect impacts on Canadian consumers, healthcare providers, and market participants.
Technical indicators suggest short-term caution, but the medium- to long-term outlook remains neutral to positive, supported by attractive dividends and strong fundamentals appealing to Canadian investors. Most moving averages and MACD signals indicate a bearish short-term trend; however, the stock’s low beta and defensive nature, as well as a consensus target price with a 10% upside, provide stability. The quarterly dividend (current yield 3.37%) remains a compelling feature for Canadian investors focused on total return and income stability, especially when held in tax-advantaged accounts. The company’s demonstrated ability to navigate regulatory, competitive, and patent-related challenges suggests ongoing strength for those with a medium- or long-term investment horizon.
FAQ
What is the latest dividend for JNJ stock?
Johnson & Johnson currently pays a quarterly dividend. The most recent dividend is $1.24 USD per share, with the next ex-dividend date set for May 27, 2025. JNJ is a Dividend Aristocrat, having raised its payout for over 60 consecutive years, making it attractive to investors seeking consistent income. The current dividend yield stands at around 3.37%, reflecting the company's commitment to returning value to shareholders.
What is the forecast for JNJ stock in 2025, 2026, and 2027?
Based on the latest share price of $154.46, projections estimate JNJ stock could reach $200.80 by the end of 2025, $231.69 by the end of 2026, and $308.92 by the end of 2027. These optimistic projections align with strong fundamentals, including robust earnings, an innovative product pipeline, and positive analyst outlook, especially as JNJ demonstrates resilience despite sector challenges.
Should I sell my JNJ shares?
Holding onto JNJ shares may be advantageous considering the company’s longstanding history of growth and stability. With a strong market position, sector leadership, and over 60 years of dividend increases, JNJ has proven its ability to navigate market cycles. Its diversified business model and strategic investments suggest potential for sustained value creation over the long term, which may favor patient investors.
Are dividends from JNJ stock eligible for tax advantages in Canada?
JNJ dividends are classified as foreign income for Canadian investors and are not eligible for the Canadian dividend tax credit. While they can be held in tax-advantaged accounts like RRSPs or TFSAs, a 15% U.S. withholding tax typically applies—though this can be avoided if JNJ shares are held in an RRSP. Capital gains from JNJ shares are subject to standard Canadian taxation rules.
What is the latest dividend for JNJ stock?
Johnson & Johnson currently pays a quarterly dividend. The most recent dividend is $1.24 USD per share, with the next ex-dividend date set for May 27, 2025. JNJ is a Dividend Aristocrat, having raised its payout for over 60 consecutive years, making it attractive to investors seeking consistent income. The current dividend yield stands at around 3.37%, reflecting the company's commitment to returning value to shareholders.
What is the forecast for JNJ stock in 2025, 2026, and 2027?
Based on the latest share price of $154.46, projections estimate JNJ stock could reach $200.80 by the end of 2025, $231.69 by the end of 2026, and $308.92 by the end of 2027. These optimistic projections align with strong fundamentals, including robust earnings, an innovative product pipeline, and positive analyst outlook, especially as JNJ demonstrates resilience despite sector challenges.
Should I sell my JNJ shares?
Holding onto JNJ shares may be advantageous considering the company’s longstanding history of growth and stability. With a strong market position, sector leadership, and over 60 years of dividend increases, JNJ has proven its ability to navigate market cycles. Its diversified business model and strategic investments suggest potential for sustained value creation over the long term, which may favor patient investors.
Are dividends from JNJ stock eligible for tax advantages in Canada?
JNJ dividends are classified as foreign income for Canadian investors and are not eligible for the Canadian dividend tax credit. While they can be held in tax-advantaged accounts like RRSPs or TFSAs, a 15% U.S. withholding tax typically applies—though this can be avoided if JNJ shares are held in an RRSP. Capital gains from JNJ shares are subject to standard Canadian taxation rules.
